Viva Biotech Holdings Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,089	941.58	1,036	678.57	800.95
Cash & Short-Term Investments	1,089	941.58	1,036	678.57	800.95
Cash Growth	15.63%	-9.14%	52.72%	-15.28%	-66.03%
Accounts Receivable	386.3	420.46	407.41	445.97	429.7
Other Receivables	242.94	61.24	136.13	59.41	102.2
Receivables	629.24	481.7	543.53	505.38	531.9
Inventory	335.74	272.7	259.71	326.03	231.72
Prepaid Expenses	9.34	8.31	5.95	7.94	7.26
Other Current Assets	65.1	172.31	185.41	420.88	411.95
Total Current Assets	2,128	1,877	2,031	1,939	1,984
Property, Plant & Equipment	1,535	1,597	1,655	1,937	1,724
Long-Term Investments	873.57	988.55	1,038	1,047	1,247
Goodwill	2,156	2,156	2,156	2,156	2,156
Other Intangible Assets	311.49	366.05	420.67	476.06	531.44
Long-Term Accounts Receivable	2.93	3.51	5.25	6.43	16.12
Long-Term Deferred Tax Assets	35.86	21.8	21.19	18.18	7.63
Other Long-Term Assets	156.21	40.36	122.76	340.97	378.73
Total Assets	7,199	7,051	7,450	7,921	8,045
Accounts Payable	212.24	309.36	245.76	326.13	281.05
Accrued Expenses	101.12	97.96	133.35	140.37	105.85
Short-Term Debt	575.33	261.31	538.03	373.94	228.9
Current Portion of Long-Term Debt	394.23	288.08	411.48	1,540	4.15
Current Portion of Leases	2.79	3.09	2.93	2.27	5.69
Current Income Taxes Payable	23.23	28.87	32.02	41.63	41.31
Current Unearned Revenue	38.46	50.98	36.42	44.24	50.01
Other Current Liabilities	63.76	87.01	134.19	204	209.64
Total Current Liabilities	1,411	1,127	1,534	2,673	926.6
Long-Term Debt	331.19	705.92	922.01	880.96	2,388
Long-Term Leases	27.05	25.65	28.76	25.8	27.77
Long-Term Unearned Revenue	29.42	33	55.02	73.12	75.27
Long-Term Deferred Tax Liabilities	68.2	73.85	69.19	92.2	117.73
Other Long-Term Liabilities	1,326	1,269	1,153	571.5	595.85
Total Liabilities	3,193	3,234	3,762	4,316	4,131
Common Stock	0.36	0.37	0.37	0.33	0.33
Additional Paid-In Capital	-	3,874	3,874	3,637	3,637
Retained Earnings	-	-127.21	-294.51	-178.4	350.08
Treasury Stock	-129.04	-157.67	-134.65	-134.65	-134.65
Comprehensive Income & Other	4,125	212.73	242.54	280.48	60.65
Total Common Equity	3,997	3,802	3,688	3,605	3,913
Minority Interest	9.78	13.84	-	-	-
Shareholders' Equity	4,006	3,816	3,688	3,605	3,913
Total Liabilities & Equity	7,199	7,051	7,450	7,921	8,045
Total Debt	1,331	1,284	1,903	2,823	2,655
Net Cash (Debt)	-241.82	-342.47	-866.9	-2,144	-1,854
Net Cash Per Share	-0.10	-0.12	-0.43	-1.12	-0.94
Filing Date Shares Outstanding	2,111	2,113	2,142	1,915	1,915
Total Common Shares Outstanding	2,111	2,113	2,142	1,915	1,915
Working Capital	717.03	749.94	496.74	-733.75	1,057
Book Value Per Share	1.89	1.80	1.72	1.88	2.04
Tangible Book Value	1,529	1,280	1,111	972.23	1,225
Tangible Book Value Per Share	0.72	0.61	0.52	0.51	0.64
Buildings	-	759.47	558.65	553.56	293.19
Machinery	-	926.64	805.36	703.13	552.49
Construction In Progress	-	109.54	338.48	469.88	542.03
Leasehold Improvements	-	26.29	26.29	26.29	37.07
Order Backlog	-	-	-	-	965

Source: S&P Global Market Intelligence. Standard template. Financial Sources.